 I. Demonstrate if the combination of letrozole and ribociclib LEE011 leads to a higher cancer antigen 125 CA-125 response rate in patients with relapsed ER positive ovarian cancers and endometrial cancers as compared to that observed in previously reported single agent letrozole studies. 